Coherus BioSciences (CHRS) Misses Q3 EPS by 22c, Misses on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $0.83 -7.78%
EPS Growth %: +39.4%
Financial Fact:
Depreciation and amortization: 14.21M
Today's EPS Names:
OPY, BNCC, ZVOI, More
EPS Growth %: +39.4%
Financial Fact:
Depreciation and amortization: 14.21M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($0.96), $0.22 worse than the analyst estimate of ($0.74). Revenue for the quarter came in at $45.4 million versus the consensus estimate of $57.27 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Assumes Coherus Biosciences (CHRS) at Buy
- New Break Resources plans $550,000 flow-through share offering
- Norwegian Cruise (NCLH) PT Raised to $22 at Freedom Broker, Upgrades to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
